Dengvaxia Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The dengvaxia market size has grown rapidly in recent years. It will grow from $213.36 million in 2025 to $250.81 million in 2026 at a compound annual growth rate (CAGR) of 17.6%. The growth in the historic period can be attributed to recurring dengue outbreaks, high disease burden in tropical regions, government led immunization initiatives, limited treatment options for dengue, rising public health awareness.

The dengvaxia market size is expected to see rapid growth in the next few years. It will grow to $473.95 million in 2030 at a compound annual growth rate (CAGR) of 17.2%. The growth in the forecast period can be attributed to expansion of vaccination coverage, increasing climate driven mosquito spread, growth in public health funding, improved vaccine delivery infrastructure, rising travel related immunization demand. Major trends in the forecast period include expansion of dengue vaccination programs, growing focus on endemic disease prevention, rising public health immunization campaigns, increased surveillance of mosquito-borne diseases, strengthening of pediatric and adolescent vaccination.

The high incidence of dengue is expected to drive the growth of the dengvaxia market in the coming years. Dengue is a viral infection transmitted by Aedes mosquitoes, causing flu-like symptoms, severe pain, and in extreme cases, life-threatening complications such as dengue hemorrhagic fever or dengue shock syndrome. The rising prevalence of dengue is fueled by climate change, urbanization, increased travel, and the expansion of mosquito breeding grounds, leading to higher infection rates and greater demand for prevention and treatment. Dengvaxia helps prevent dengue by stimulating the immune system to produce a protective response against the virus, reducing the risk of infection and severe complications, and improving public health outcomes in endemic regions. For example, in June 2024, the Centers for Disease Control and Prevention (CDC) reported that the Americas recorded over 9.7 million dengue cases, double the 4.6 million cases in 2023. Puerto Rico declared a public health emergency with 1,498 cases, and 745 cases were reported among U.S. travelers. Consequently, the high incidence of dengue is driving the growth of the dengvaxia market.

Rising healthcare expenditures are also expected to accelerate the growth of the dengvaxia market. Healthcare expenditure refers to the financial resources allocated by governments, private entities, or individuals for healthcare services, treatments, and related activities. Increases in healthcare spending are driven by growing demand for medical services, technological advancements, and the rising prevalence of chronic and infectious diseases, leading to greater investment in infrastructure and treatments. Expenditure on Dengvaxia emphasizes prevention, aiming to reduce the long-term costs of treating dengue and managing outbreaks. For instance, in May 2024, the Office for National Statistics reported that total healthcare expenditure in the UK increased by 5.6% in nominal terms from 2022 to 2023, a notable acceleration compared to the 0.9% growth observed in 2022. Therefore, growing healthcare spending is supporting the expansion of the dengvaxia market.

The rise in international travel is also expected to propel the growth of the dengvaxia market. International travel, including tourism, business, or educational trips, increases the risk of spreading infectious diseases such as dengue, which drives demand for preventive measures like vaccines. Dengvaxia is used to protect travelers from contracting dengue in endemic regions and to reduce the risk of cross-border disease transmission. For example, in May 2024, the Office for National Statistics reported that international visits to the UK increased from 31.2 million in 2022 to 38 million in 2023. Therefore, rising international travel is contributing to the growth of the dengvaxia market.

Major companies operating in the dengvaxia market are Sanofi Pasteur Inc.

Asia-Pacific was the largest region in the dengvaxia market in 2025. Latin America is expected to be the fastest-growing region in the forecast period. The regions covered in the dengvaxia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dengvaxia market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the dengvaxia market by increasing costs related to imported vaccine raw materials, cold chain packaging, and specialized manufacturing inputs. These cost pressures have affected public health procurement programs, particularly in developing and dengue endemic regions. Asia pacific and latin america are most exposed due to high reliance on imported vaccines. At the same time, tariffs have encouraged regional vaccine manufacturing, strengthened local supply chains, and improved long term vaccine accessibility.

The dengvaxia market research report is one of a series of new reports that provides dengvaxia market statistics, including dengvaxia industry global market size, regional shares, competitors with a dengvaxia market share, detailed dengvaxia market segments, market trends and opportunities, and any further data you may need to thrive in the dengvaxia industry. This dengvaxia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dengvaxia is a recombinant vaccine designed to protect against dengue fever, a viral illness transmitted by Aedes mosquitoes. It works by stimulating the immune system to generate a targeted response, helping prevent infection and severe complications, and supporting public health efforts in dengue-endemic regions.

The main types of dengvaxia include Dengvaxia itself and other related formulations. It is the first dengue vaccine approved for use, providing immunity against the virus that causes dengue and reducing the severity and frequency of infections. Dengvaxia is used in countries where dengue is prevalent to protect high-risk populations. It is distributed through hospitals, clinics, and public health programs, and applied in clinical settings for prevention in previously infected individuals, protection in high-risk areas, traveler immunization, and pediatric and adolescent use.

The dengvaxia market consists of sales of dengvaxia (CYD-TDV), disposable syringes and needles, pre-filled syringes of dengvaxia, and unit-dose packaging. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.